Mark is a European Patent Attorney with over 20 years of relevant industry experience.
Prior to joining Biotalys in 2019, he was Director, European Patent Attorney at Merus, a clinical-stage oncology company developing innovative bi-specific antibody therapeutics. Before that, he worked as European Patent Attorney at DSM and Amsterdam Molecular Therapeutics, The Netherlands, and J.A Kemp & Co in the UK.
Mark has a technical background in plant sciences and specialist experience in industrial biotechnology and antibody and gene therapeutics.
Mark obtained a BSc in Plant Sciences from the University of Cambridge and a PhD in Genetics from the John Innes Centre, Norwich.